Key result
Cangrelor serves as a peri-procedural bridge therapy prior to surgeries, restoring platelet function within 60 minutes of cessation to decrease bleeding risk while reducing ischemic events.
Why the study?
Cangrelor has emerged as a potential bridge therapy for antiplatelet medication before cardiac and non-cardiac surgeries, prompting a review of its role as a peri-procedural bridge.
Does intravenous cangrelor provide effective peri-procedural bridging for patients requiring antiplatelet therapy?
Does intravenous cangrelor provide effective peri-procedural bridging for patients requiring antiplatelet therapy?
Cangrelor's rapid offset of action allows for restoration of platelet function within 60 minutes, supporting its use as a peri-procedural bridge to minimize both bleeding and ischemic risks.
Supports cangrelor bridging in P2Y12-treated patients awaiting surgery; reinforces RCT evidence for maintained inhibition without excess bleeding.
Cangrelor is a relatively new antiplatelet drug that has been approved for use as an adjunct therapy to percutaneous coronary intervention (PCI) to decrease peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis. Cangrelor is an adenosine triphosphate analogue with a pharmacokinetic mechanism based on a reversible, dose-dependent inhibition adenosine diphosphate (ADP)-induced platelet aggregation. This drug has lately been in the spotlight as a possible bridge therapy for anti-platelet medication prior to cardiac and non-cardiac surgeries. Platelet function is usually restored within sixty minutes of cessation of therapy, thereby decreasing the risk of bleeding while providing adequate pre-procedural coverage to reduce ischemic events. This manuscript reviews the literature on cangrelor and summarizes its role as a peri-procedural bridge.
No takes yet. Share an insight, caveat, or question.
Bhattad et al. (2019) conducted a review in Patients requiring anti-platelet medication prior to surgeries. Cangrelor was evaluated. Cangrelor serves as a peri-procedural bridge therapy prior to surgeries, restoring platelet function within 60 minutes of cessation to decrease bleeding risk while reducing ischemic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: